Related Experiment Video
Updated: Sep 29, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
[Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate
K S Delank1, T Hansen, P Eysel
1Orthopädische Universitätsklinik Köln, Germany. Karl-Stefan.Delank@medizin.uni-koeln.de
Aim:
The long-term results of rheumatoid arthritis are unsatisfactory despite the mono or combination therapy of conventional "disease-modifying antirheumatic drugs". Therefore in the recent past the administration of a combination of Methotrexate with Leflunomide takes place more frequently. To what extent the perioperative infection rate is influenced by the individual immune-modulating drugs, is still disputed and should quantified on the basis the rheumatism orthopaedic patient collective of an orthopaedic university clinic.
Method:
The clinical progresses of patients after operative treatment in the orthopaedic hospital, since introduction of the Leflunomide, were evaluated with regard to perioperative infection.
Results:
Of 16 patients, who were observed during a period of 1,5 years under a combination therapy by MTX/Leflunomide, three exhibited a heavy infection of the musculoskeletal system.
Conclusion:
The combination of the two above mentioned drugs affects different pathophysiological processes. Synergistic effects in therapy but also with regard to side effects must be expected. First available reports on this combination therapy do not refer to a increased infection/risk. The observation of three serious infections under the combination MTX/Leflunomide prompted us to call attention to this risk. In particular with infection-susceptible bone-surgical operations such a combination of immune-modulating medicines should be employed with caution. The recent literature is discussed.
Insights
The combination of Methotrexate and Leflunomide for rheumatoid arthritis may increase the risk of serious musculoskeletal infections, particularly in bone surgery patients. Caution is advised when using these immune-modulating drugs together.
Area of Science:
- Rheumatology
- Orthopaedic Surgery
- Infectious Disease
Background:
- Conventional disease-modifying antirheumatic drugs (DMARDs) show unsatisfactory long-term results for rheumatoid arthritis.
- Combination therapy with Methotrexate (MTX) and Leflunomide is increasingly used.
- The impact of these immune-modulating drugs on perioperative infection rates remains debated.
Observation:
- A study evaluated 16 patients undergoing orthopaedic surgery on MTX/Leflunomide combination therapy over 1.5 years.
- Three patients (18.75%) developed severe musculoskeletal infections during the observation period.
Findings:
- The combination of MTX and Leflunomide may be associated with an increased risk of serious infections.
- Synergistic effects on both therapeutic outcomes and side effects are possible.
- This finding contrasts with previous reports suggesting no increased infection risk.
Implications:
- Clinicians should exercise caution when prescribing MTX/Leflunomide combination therapy, especially for patients undergoing bone surgery.
- Further research is needed to fully elucidate the infection risks associated with this drug combination.
- This highlights the importance of monitoring for infections in patients on combined immune-modulating therapy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease I: Introduction